ArticleJournal of nanobiotechnology2026
Fisetin-loaded nanoparticles as a novel approach for cholesterol regulation in hypercholesterolemia: targeting the ASGR1-mediated mTORC1/AMPK pathway.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fisetin Attenuates D-Gal-Induced Ovarian Aging by Modulating Mitophagy via the AMPK/mTOR Pathway.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Hypercholesterolemia is a major risk factor for the development of atherosclerotic cardiovascular disease. The flavonoid fisetin shows potential cholesterol-regulating effects. Nevertheless, poor solubility and low bioavailability limit its clinical application. This study investigates fisetin's effects on hypercholesterolemia and underlying mechanisms. Using a hypercholesterolemic mouse model, we observe that fisetin significantly attenuates hepatic steatosis, decreases total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, and alleviates oxidative stress. Consistent results are observed in cellular experiments. Fisetin administration markedly modulates hepatic proteins involved in cholesterol excretion (ABCA1, ABCG5, ABCG8, CYP7A1, and LXRα) and cholesterol metabolism (HMGCR, LDLR, and SR-B1), thereby maintaining cholesterol homeostasis. Mechanistically, fisetin targets asialoglycoprotein receptor 1 (ASGR1), modulating the mTORC1/AMPK-BRCA1/BARD1 pathway. Notably, ASGR1 overexpression counteracts fisetin's cholesterol-lowering effects. Additionally, carboxymethyl chitosan (CMCS)-modified β-cyclodextrin (β-CD)-based fisetin nanoparticles notably reduce lipid accumulation, TC and TG levels, even at concentrations one-fifth of free fisetin. In summary, fisetin effectively modulates cholesterol metabolism and represents a promising therapeutic approach for managing hypercholesterolemia. The fisetin nanoparticles offer an innovative strategy to overcome fisetin's clinical limitations, enhancing its bioavailability and therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.